Correlation Between Incyte and Apellis Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Incyte and Apellis Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Incyte and Apellis Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Incyte and Apellis Pharmaceuticals, you can compare the effects of market volatilities on Incyte and Apellis Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Incyte with a short position of Apellis Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Incyte and Apellis Pharmaceuticals.
Diversification Opportunities for Incyte and Apellis Pharmaceuticals
-0.18 | Correlation Coefficient |
Good diversification
The 3 months correlation between Incyte and Apellis is -0.18. Overlapping area represents the amount of risk that can be diversified away by holding Incyte and Apellis Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Apellis Pharmaceuticals and Incyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Incyte are associated (or correlated) with Apellis Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Apellis Pharmaceuticals has no effect on the direction of Incyte i.e., Incyte and Apellis Pharmaceuticals go up and down completely randomly.
Pair Corralation between Incyte and Apellis Pharmaceuticals
Given the investment horizon of 90 days Incyte is expected to generate 0.32 times more return on investment than Apellis Pharmaceuticals. However, Incyte is 3.14 times less risky than Apellis Pharmaceuticals. It trades about 0.24 of its potential returns per unit of risk. Apellis Pharmaceuticals is currently generating about -0.06 per unit of risk. If you would invest 6,907 in Incyte on November 1, 2024 and sell it today you would earn a total of 465.00 from holding Incyte or generate 6.73% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Incyte vs. Apellis Pharmaceuticals
Performance |
| Timeline |
| Incyte |
| Apellis Pharmaceuticals |
Incyte and Apellis Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Incyte and Apellis Pharmaceuticals
The main advantage of trading using opposite Incyte and Apellis Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Incyte position performs unexpectedly, Apellis Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apellis Pharmaceuticals will offset losses from the drop in Apellis Pharmaceuticals' long position.| Incyte vs. Alnylam Pharmaceuticals | Incyte vs. United Therapeutics | Incyte vs. Ultragenyx | Incyte vs. Apellis Pharmaceuticals |
| Apellis Pharmaceuticals vs. Akero Therapeutics | Apellis Pharmaceuticals vs. Immunovant | Apellis Pharmaceuticals vs. Madrigal Pharmaceuticals | Apellis Pharmaceuticals vs. Day One Biopharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Complementary Tools
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |